Kerry O. Cleveland

ORCID: 0000-0003-1278-9662
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Antimicrobial Resistance in Staphylococcus
  • Bacterial Identification and Susceptibility Testing
  • Antifungal resistance and susceptibility
  • Fungal Infections and Studies
  • Antibiotics Pharmacokinetics and Efficacy
  • Infective Endocarditis Diagnosis and Management
  • Infectious Diseases and Tuberculosis
  • Streptococcal Infections and Treatments
  • Antibiotic Resistance in Bacteria
  • Orthopedic Infections and Treatments
  • Antibiotic Use and Resistance
  • Bacterial Infections and Vaccines
  • Infections and bacterial resistance
  • Pneumonia and Respiratory Infections
  • Nail Diseases and Treatments
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Drug-Induced Adverse Reactions
  • Clostridium difficile and Clostridium perfringens research
  • Otolaryngology and Infectious Diseases
  • Urinary Tract Infections Management
  • Mycobacterium research and diagnosis
  • Infectious Encephalopathies and Encephalitis
  • Neutropenia and Cancer Infections
  • Central Venous Catheters and Hemodialysis
  • Pharmacological Effects and Toxicity Studies

University of Tennessee Health Science Center
2015-2025

Methodist University Hospital
1999-2023

Methodist Le Bonheur Healthcare
2019-2023

Office of Infectious Diseases
2006-2018

Methodist Healthcare
2014

Weatherford College
2014

Cubist Pharmaceuticals (United States)
2013

Le Bonheur Children's Hospital
2004

Houston Methodist
1999

Methodist Hospital
1999

Abstract A 56-year-old female patient presented with severe abdominal pain and intra-abdominal/retroperitoneal fluid collections growing Escherichia coli vancomycin-resistant Enterococcus faecium ; oral linezolid cefdinir were prescibed. Pancreatic enzymes, lactate, serum chemistry studies, blood glucose unremarkable during initial hospitalization. The remained afebrile leukocytosis resolved antibiotics. On day 37 of therapy, was 56 mg/dL bicarbonate 17 mEq/L (normal 23–30 mEq/L). As the...

10.1097/ipc.0000000000001436 article EN Infectious Diseases in Clinical Practice 2025-01-22

Among the endemic mycoses, blastomycosis has been least often associated with disorders of immune function, but data presented herein suggest that may occur more commonly in immunocompromised patients than was previously recognized. We have observed a marked increased number over last 15 years, increasing from about 3% seen between 1956 and 1977 to almost 24% 1978 1991. The disease appears be much aggressive normal hosts. Almost 30% our series died secondary blastomycosis, most deaths...

10.1097/00005792-199309000-00003 article EN Medicine 1993-09-01

Central nervous system (CNS) involvement occurs in 5 to 10% of individuals with disseminated histoplasmosis. Most experience has been derived from small single center case series, or report literature reviews. Therefore, a larger study central histoplasmosis is needed order guide the approach diagnosis, and treatment. A convenience sample 77 patients infection CNS was evaluated. Data collected that focused on recognition infection, diagnostic techniques, outcomes Twenty nine percent were not...

10.1097/md.0000000000010245 article EN cc-by-nc Medicine 2018-03-01

Pooled data from two large registries, Cubicin® Outcomes Registry and Experience (CORE; USA) European (EU-CORE; Europe, Latin America, Asia), were analyzed to determine the characteristics clinical outcomes of daptomycin therapy in patients with Gram-positive infections across wide geographical regions. Patients receiving at least one dose between 2004 2012 for treatment included. Clinical success was defined as an outcome 'cured' or 'improved'. Post-treatment follow-up collected a subset...

10.1186/s12941-016-0130-8 article EN cc-by Annals of Clinical Microbiology and Antimicrobials 2016-03-15

Eravacycline is a novel, fully-synthetic tetracycline approved by the FDA for treatment of complicated intra-abdominal infections in August 2018. This study sought to characterise early clinical experience with this novel antibiotic.Eravacycline utilisation 66 patients was retrospectively evaluated.Eravacycline used as monotherapy 62.1% cases. Mean duration therapy 13.1 ± 9.9 days. The majority (68.2%) off-label indications, including 34.8% pulmonary and 28.8% skin/soft tissue infections. A...

10.1016/j.jgar.2021.10.020 article EN cc-by-nc-nd Journal of Global Antimicrobial Resistance 2021-11-14

Adenoviruses are well documented as opportunistic pathogens in patients with immunocompromising conditions, including human immunodeficiency virus (HIV) infection. We recently diagnosed adenovirus infection of the parotid gland two AIDS. Viral cultures and electron microscopic examinations tissue were positive both cases. Adenovirus should be considered differential diagnosis swelling HIV-infected patients.

10.1093/clinids/19.6.1045 article EN Clinical Infectious Diseases 1994-12-01

Systemic histoplasmosis is uncommonly reported in patients who have undergone bone marrow or solid organ transplantation. Diagnosis of systemic recipients transplants may be hampered by lack consideration this infection the differential diagnosis and confounded conflicting information from other testing performed to evaluate for opportunistic infections population. We report successful treatment a case disseminated patient with Hodgkin's lymphoma had autologous stem cell The was delayed...

10.1111/j.1399-3062.2009.00381.x article EN Transplant Infectious Disease 2009-03-16

Abstract Background Data are limited regarding use of piperacillin/tazobactam for ESBL urinary tract infections (UTIs). The objective this study was to compare clinical outcomes patients treated empirically with versus carbapenems UTIs. Methods This retrospective, observational, propensity score-matched evaluated adults an on urine culture. Patients who had UTI symptoms or leukocytosis, and received a carbapenem at least 48 h were included. primary outcome success within h, defined as...

10.1093/jacamr/dlad055 article EN cc-by JAC-Antimicrobial Resistance 2023-05-03

Bordetella bronchiseptica bacteremia is often associated with various infection in animals. The majority of B infections reported humans are cases pneumonia. Very few have been patients a history acquired immune deficiency syndrome (AIDS). patient described herein, who had AIDS, was likely infected as result his hemodialysis catheter. successfully treated antibiotics without the removal

10.1097/smj.0b013e3181ebcdbc article EN Southern Medical Journal 2010-09-01

Vancomycin therapy is the standard treatment for methicillin-resistant Staphylococcus aureus (MRSA), most common cause of vertebral osteomyelitis, an increasingly frequent complication nosocomial bacteremia. We report five recent cases suggesting that, while giving appearance success by conventional clinical and laboratory criteria (eg, resolution fever leukocytosis), vancomycin monotherapy may in fact be insufficient to prevent or reverse progression hematogenous MSRA osteomyelitis. A...

10.1097/00007611-200406000-00017 article EN Southern Medical Journal 2004-06-01

A 55-year-old man with Laennec cirrhosis and a MELD score of 24 underwent orthotopic liver transplantation. Post-operatively his recovery was complicated by development sepsis syndrome fever respiratory failure. Antimicrobial coverage broad-spectrum antibacterials, fluconazole 400 mg IV daily, prophylactic doses oral trimethoprim/sulfamethoxazole valganciclovir as well immunosuppressive treatment sirolimus, mycophenolate mofetil intermittent lymphocyte immune globulin, anti-thymocyte, were...

10.1093/qjmed/hcs133 article EN QJM 2012-07-28

Background Vertebral osteomyelitis is caused predominantly by Staphylococcus aureus, which increasingly methicillin resistant. Our objective was to compare outcomes after use of vancomycin and daptomycin for treatment vertebral osteomyelitis. Methods We conducted a retrospective chart review all patients who received diagnosis over 6-year period at tertiary care hospital in Memphis, Tennessee. Results Sixty-one were identified either (n = 30) or 31) had follow-up least 12 months. The mean...

10.1097/ipc.0000000000000116 article EN Infectious Diseases in Clinical Practice 2013-10-17

Bacteremia and endocarditis caused by Staphylococcus aureus (S. aureus), particularly methicillin-resistant S. (MRSA), are challenging to treat associated with high morbidity mortality. Telavancin is a lipoglycopeptide antibacterial active against susceptible Gram-positive pathogens, including MRSA.This registry study assessed the real-world use clinical outcomes of telavancin in patients bacteremia or enrolled Observation Use Registry (TOUR™).The subset TOUR who were diagnosed and/or known...

10.1007/s40801-020-00191-x article EN cc-by-nc Drugs - Real World Outcomes 2020-05-05
Coming Soon ...